Subject:
- Active Substance: Sutimlimab
- Name: Enjaymo®
- Therapeutic area: Cold agglutinin disease (CAD)
- Pharmaceutical company: Lilly Deutschland GmbH
Time table:
- Start: 01.01.2023
- Final decision by G-BA: 15.06.2023
Final decision:
- Hint for a minor additional benefit